hypertnsn rough

7/29/2019 Hypertnsn Rough

1/13

Click to edit Master subtitle style

2/24/13

MARKET ASSESSMENTCASE STUDY :

HYPERTENSION

Presented By :Vartika Yadav BM 13

Tanvi Patil BM 18Gargi Indurkar BM 20

Pooja Jadhav BM- 21Shweta Bansal BM - 23

Presented To: Prof. Suhas Tambe


2/13

2/24/13

Objective

To find out the potential patient poolof hypertension for a leadingpharmaceutical company in five

European Union countries.


3/13

2/24/13

Overview :Introduction

Hypertension / HTN HighBlood Pressure or ArterialHypertension.

Chronic condition, blood pressure inarteries is elevated.

BP : classified by two measurements.

Systolic : Blood pressure within range of100-140 mmHg.

Diastolic : Blood pressure within range of

60-90 mmHg.


4/13

2/24/13

Hypertension is also classified : Primary (essential)and Secondary hypertension.

Primary Hypertension : 90-95% cases , which meanshigh bp with no underlying medical cause.

Secondary Hypertension : 5-10% cases, caused by

other conditions that have an effect on kidneys,arteries, heart or endocrine system.

CLASSIFICATION

SYSTOLICPRESSURE

DIASTOLICPRESSURE

mmHg kPa mmHg kPa

Normal 90119 1215.9 6079 8.010.5

Prehypertension 120139 16.018.5 8089 10.711.9

Stage 1 140159 18.721.2 9099 12.013.2

Stage 2 160 21.3 100 13.3

Isolated systolichypertension

140 18.7


5/13

2/24/13

Causes


6/13

2/24/13

Symptoms

P


7/13

2/24/13

Prevent on anManagement

Maintain normalbody weight .

Reduce dietary

sodium intake. Engage in regular

aerobic physical

activity such asbrisk walking.

Limit alcohol

consumption to no

Lifestylemodifications

Medications

Drug Combinations:viz,

calcium channelblockers anddiuretics, beta-blockers and

diuretics,


8/13

2/24/13

Epidemiology

Source : JAMA. 2003;289(18):2363-2369. doi:10.1001/jama.289.18.2363


9/13

2/24/13

Prevalence : Age

The prevalence in the age group 35 to 44 years was 14% in the North American countries and27% in Europe, increasing to 53% and 78%, respectively, among persons aged 65 to 74 years.


10/13

2/24/13

Prevalence : Mortality

Source : JAMA. 2003;289(18):2363-2369. doi:10.1001/jama.289.18.2363

C lid t d ti t l d


11/13


2/24/13

Consolidated patient pool andepidemiology of

hypertension(2011)Country Incidences Total

PopulationPatient pool

UK 41.7% 5,83,54,430 2,43,33,797

Spain 46.8% 3,94,78,150 1,84,75,774

Germany 55.3% 8,20,12,000 4,53,52,636

Italy 37.7% 5,68,62,800 2,14,37,275

France 29.7% 5,80,26,000 1,72,33,722

ConsolidatedPatient Pool

43.03%29,47,33,380

12,68,33,204


12/13


2/24/13

Population vs. PatientPool

0

1

2

3

4

5

6

7

8

910


13/13


2/24/13

MARKET ESTIMATION

The markets of the developing world are alteringmore radically than those of the developed worldHypertension (>1B patients by 2025)Diabetes (84m in 1995 to 228m in 2025 >70M in India

alone)

By the 2020 the global Pharmaceuticals marketwill be worth about $1.3 Trillion ($800Billion today)

hypertnsn rough

Documents